Holen Sie sich die Stockscreener-App
68.98
1.52%
1.03
Handel nachbörslich:
69.00
0.02
+0.03%
Schlusskurs vom Vortag:
$67.95
Offen:
$67.85
24-Stunden-Volumen:
1.75M
Relative Volume:
0.66
Marktkapitalisierung:
$15.34B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$556.70M
KGV:
29.11
EPS:
2.37
Netto-Cashflow:
$970.10M
1W Leistung:
+3.12%
1M Leistung:
+4.96%
6M Leistung:
+8.43%
1J Leistung:
-15.41%
1-Tages-Spanne:
$67.77
$69.13
1-Wochen-Bereich:
$66.78
$69.13
52-Wochen-Spanne:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
Firmenname
Hologic Inc
Sektor
Telefon
(508) 263-2900
Adresse
250 CAMPUS DRIVE, MARLBOROUGH, MA
Vergleichen Sie HOLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
68.98 | 15.11B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
482.35 | 171.42B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.96 | 55.88B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.48 | 42.55B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
288.28 | 41.48B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.22 | 17.25B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-27 | Bestätigt | Needham | Hold |
| 2025-03-03 | Herabstufung | Argus | Buy → Hold |
| 2025-02-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Herabstufung | Needham | Buy → Hold |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-12-10 | Bestätigt | Needham | Buy |
| 2024-10-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-27 | Eingeleitet | Stephens | Overweight |
| 2024-04-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-14 | Hochstufung | Needham | Hold → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-07-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-07-18 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Herabstufung | Needham | Buy → Hold |
| 2020-11-05 | Bestätigt | Needham | Buy |
| 2020-06-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-06-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Bestätigt | Needham | Buy |
| 2020-04-30 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-01-31 | Bestätigt | Needham | Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-09-13 | Herabstufung | BofA/Merrill | Buy → Neutral |
Alle ansehen
Hologic Inc Aktie (HOLX) Neueste Nachrichten
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength - Yahoo Finance
Body Fat Measurement Market to Witness Growth and Comprehensive - openPR.com
Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Stock Analysis | Hologic OutlookMixed Signals Amid Strong Fundamentals - AInvest
HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum - FinancialContent
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - uk.finance.yahoo.com
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It? - The Globe and Mail
Hologic's Diagnostics Arm Set For Long-Term Upside: What's Behind It? - Barchart.com
There May Be Some Bright Spots In Hologic's (NASDAQ:HOLX) Earnings - Yahoo Finance
RadNet hires Hologic, Bausch + Lomb alum Jane Mazur - Medical Marketing and Media
Hologic’s Growth Story Looks Set For A Comeback - Finimize
RBC Capital Reiterates Buy Rating for Hologic with $87 Price Target - AInvest
RBC Capital Upgrades Hologic (HOLX) to Outperform with Raised Pr - GuruFocus
Forecasting the Future: Next-Generation Biopsy-Based Cancer - openPR.com
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings? - The Globe and Mail
Should You Buy, Sell Or Hold Hologic Stock Post Q3 Earnings? - Barchart.com
Hpv And Pap Testing Market Generated Opportunities, Future - openPR.com
RBC Capital Upgrades Hologic to Outperform From Sector Perform, Adjusts PT to $87 From $72 - MarketScreener
RBC Capital upgrades Hologic stock to Outperform on expected growth By Investing.com - Investing.com Canada
RBC Capital upgrades Hologic stock to Outperform on expected growth - Investing.com
Molecular Diagnostics Market Expands with Infectious Disease - openPR.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report - simplywall.st
Why Hologic (HOLX) is a Top Value Stock for the Long-Term - Yahoo Finance
Interpreting Hologic (HOLX) International Revenue Trends - Yahoo Finance
What are analysts’ price targets for Hologic Inc. in the next 12 monthsMassive portfolio appreciation - Jammu Links News
Is Hologic Inc. a good long term investmentIdentify winners with top-tier analysis - Jammu Links News
Hologic, Inc. (NASDAQ:HOLX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - 富途牛牛
Hologic's Q3 Earnings Beat and Strategic Innovations: A Convincing Case for Value Investors - AInvest
Hologic Analyst Estimates: Third-Quarter Report Recap - AInvest
Analyst Estimates: Here's What Brokers Think Of Hologic, Inc. (NASDAQ:HOLX) After Its Third-Quarter Report - Yahoo Finance
What makes Hologic Inc. stock price move sharplyFree Predictions - Jammu Links News
What are Hologic Inc. company’s key revenue driversAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is it the right time to buy Hologic Inc. stockCapitalize on emerging market opportunities - Jammu Links News
Is Hologic Inc. stock overvalued or undervaluedIdentify safe investments with exceptional yields - Jammu Links News
What institutional investors are buying Hologic Inc. stockSpectacular growth rates - Jammu Links News
How does Hologic Inc. compare to its industry peersMaximize returns with strategic trading plans - Jammu Links News
Published on: 2025-08-03 05:06:54 - Jammu Links News
Hologic targets mid-single-digit organic revenue growth in 2026 as Breast Health rebounds and tariff mitigation advances - MSN
What is the risk reward ratio of investing in Hologic Inc. stockGet timely alerts on top market movers - Jammu Links News
Hologic, Inc. (NASDAQ:HOLX) Q3 2025 Earnings Call Transcript - Insider Monkey
Hologic’s Earnings Call: Strong Q3 Performance and Optimism - The Globe and Mail
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - MSN
BioZorb Lawsuit and Settlement Information: August 2025 - AboutLawsuits.com
Hologic (HOLX) Gets a Buy from J.P. Morgan - The Globe and Mail
Finanzdaten der Hologic Inc-Aktie (HOLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):